Search

Your search keyword '"Attalah, Habiba"' showing total 14 results
Start Over Author "Attalah, Habiba"
14 results on '"Attalah, Habiba"'

2. Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM)

Author

Cluzeau, Thomas, primary, Sebert, Marie, additional, Rahmé, Ramy, additional, Cuzzubbo, Stefania, additional, Lehmann-Che, Jacqueline, additional, Madelaine, Isabelle, additional, Peterlin, Pierre, additional, Bève, Blandine, additional, Attalah, Habiba, additional, Chermat, Fatiha, additional, Miekoutima, Elsa, additional, Rauzy, Odile Beyne, additional, Recher, Christian, additional, Stamatoullas, Aspasia, additional, Willems, Lise, additional, Raffoux, Emmanuel, additional, Berthon, Céline, additional, Quesnel, Bruno, additional, Loschi, Michael, additional, Carpentier, Antoine F., additional, Sallman, David A., additional, Komrokji, Rami, additional, Walter-Petrich, Anouk, additional, Chevret, Sylvie, additional, Ades, Lionel, additional, and Fenaux, Pierre, additional

Published
2021
Full Text
View/download PDF

3. Efficacy and Safety of Bemcentinib in Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Failing Hypomethylating Agents

Author

Kubasch, Anne Sophie, primary, Peterlin, Pierre, additional, Cluzeau, Thomas, additional, Götze, Katharina S., additional, Sockel, Katja, additional, Teipel, Raphael, additional, Jentzsch, Madlen, additional, Kayser, Sabine, additional, Attalah, Habiba, additional, Chermat, Fatiha, additional, Gloaguen, Silke, additional, Jersemann, Katja, additional, Schipp, Dorothea, additional, Giagounidis, Aristoteles, additional, McPherson, Stuart, additional, Tirado-González, Irene, additional, van de Loosdrecht, Arjan, additional, Fenaux, Pierre, additional, Platzbecker, Uwe, additional, Medyouf, Hind, additional, and Ades, Lionel, additional

Published
2020
Full Text
View/download PDF

5. APR-246 Combined with Azacitidine (AZA) in TP53 Mutated Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). a Phase 2 Study By the Groupe Francophone Des Myélodysplasies (GFM)

Author

Cluzeau, Thomas, primary, Sebert, Marie, primary, Rahmé, Ramy, primary, Cuzzubbo, Stefania, primary, Walter-petrich, Anouk, primary, Lehmann che, Jacqueline, primary, Peterlin, Pierre, primary, Beve, Blandine, primary, Attalah, Habiba, primary, Chermat, Fatiha, primary, Miekoutima, Elsa, primary, Beyne-Rauzy, Odile, primary, Recher, Christian, primary, Stamatoullas, Aspasia, primary, Willems, Lise, primary, Raffoux, Emmanuel, primary, Berthon, Céline, primary, Quesnel, Bruno, primary, Carpentier, Antoine, primary, Sallman, David A, primary, Chevret, Sylvie, primary, Ades, Lionel, primary, and Fenaux, Pierre, primary

Published
2019
Full Text
View/download PDF

6. Eprenetapopt Plus Azacitidine in -Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM).

Author

Cluzeau, Thomas, Sebert, Marie, Rahmé, Ramy, Cuzzubbo, Stefania, Lehmann-Che, Jacqueline, Madelaine, Isabelle, Peterlin, Pierre, Bève, Blandine, Attalah, Habiba, Chermat, Fatiha, Miekoutima, Elsa, Rauzy, Odile Beyne, Recher, Christian, Stamatoullas, Aspasia, Willems, Lise, Raffoux, Emmanuel, Berthon, Céline, Quesnel, Bruno, Loschi, Michael, and Carpentier, Antoine F

Published
2021
Full Text
View/download PDF

11. Granulocyte colony-stimulating factor enhances host defenses against bacterial pneumonia following peritonitis in nonneutropenic rats*

Author

Attalah, Habiba L., primary, Azoulay, Elie, additional, Yang, Kun, additional, Lasclos, Christine, additional, Jouault, Hélène, additional, Soussy, Claude-James, additional, Guillot, Thierry, additional, Brochard, Laurent, additional, Brun-Buisson, Christian, additional, Harf, Alain, additional, and Delclaux, Christophe, additional

Published
2002
Full Text
View/download PDF

14. APR-246 Combined with Azacitidine (AZA) in TP53Mutated Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). a Phase 2 Study By the Groupe Francophone Des Myélodysplasies (GFM)

Author

Cluzeau, Thomas, Sebert, Marie, Rahmé, Ramy, Cuzzubbo, Stefania, Walter-petrich, Anouk, Lehmann che, Jacqueline, Peterlin, Pierre, Beve, Blandine, Attalah, Habiba, Chermat, Fatiha, Miekoutima, Elsa, Beyne-Rauzy, Odile, Recher, Christian, Stamatoullas, Aspasia, Willems, Lise, Raffoux, Emmanuel, Berthon, Céline, Quesnel, Bruno, Carpentier, Antoine, Sallman, David A, Chevret, Sylvie, Ades, Lionel, and Fenaux, Pierre

Abstract

Introduction: TP53mutated (TP53m) MDS and AML have very poor outcome irrespective of the treatment received, including 40% responses (20% CR) with azacitidine (AZA) with short response duration and a median overall survival (OS) of about 8 months (Bejar, Blood 2014). APR-246 is a prodrug spontaneously converted to methylene quinuclidinone (MQ), a Michael acceptor that binds covalently to cysteines in mutant p53, leading to protein reconformation that reactivates its pro apoptotic and cell cycle arrest functions. The combination of AZA and APR 246 showed promising results in a phase Ib study in TP53mMDS (Sallman, ASH 2018). We report interim results of a GFM phase 2 study of AZA+ APR-246 in TP53mMDS and AML, conducted in parallel with a similar US MDS consortium study.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results